spacer
home > pmps > winter 2018 > safeguarding supplies
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Safeguarding Supplies

The EU requirements for protecting medicines against counterfeiting will become mandatory in February 2019. Consequently, pharmaceutical manufacturers are preparing to meet these demands with 2D identification codes and sealing of their sales packs. However, they should be aware that these measures alone will not guarantee a product’s integrity or authenticity. Only their combination with additional counterfeit-proof authenticity features can offer a comprehensive approach against fraud, misuse, and tampering. Customised multi-level security concepts, including analogue and digital features like near-field communication (NFC), ensure that all stakeholders – whether they are an informed expert or end-user – can be involved in the authentication process.

Counterfeit medicines are a common threat and an international challenge to all stakeholders involved in the pharma supply chain. The WHO estimates that up to 7% of all medicines in industrialised countries and 30-70% in developing countries are fakes. As the profit margins are clearly higher than those generated with drugs, such as heroin or cocaine, global counterfeiting syndicates are increasingly involved as well. All forms of administration are affected, including tablets, infusions, injections, ointments, and solutions, whether or not they require medical prescription. This poses a major risk to the safety of patients. Counterfeits are particularly widespread in developing countries in Africa and Asia and as a result of the growing number of internet pharmacies. Using diverse methods, fraudsters either circumvent the legal distribution chain or take advantage of its complexity to channel in products that have been falsified in terms of their identity, ingredients, or origin.

Many Unreported Cases

Counterfeiters use increasingly professional methods to produce detailed copies of medicine packs and fill them with ineffective, harmful, or even toxic imitations. More than a million people around the world die every year as a result, according to Interpol.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Nadine Lampka is Product Manager of Pharma-Security at Schreiner MediPharm – a business unit of Schreiner Group based in Oberschleissheim, Germany. She is in charge of defining business development strategies, as well as managing the product portfolio, which covers complete security systems tailored to customers’ specific requirements for effective anti-tampering and anti-counterfeiting protection. Nadine obtained her PhD – research on anti-cancer drugs – in chemistry from the Friedrich Alexander University in Erlangen-Nuremberg, Germany.

Arne Rehm is Product Manager of radio frequency identifcation/ NFC Solutions at Schreiner MediPharm. He is responsible for developing new markets and smart solutions for diverse applications in pharmaceuticals and medical devices. Prior to joining Schreiner MediPharm in 2012, Arne worked as a consultant and research associate at the Institute for Economic Studies of Medium-sized Companies at the University of Trier, Germany, focusing on innovation management and strategic marketing. He graduated in business administration.
spacer
Dr Nadine Lampka
spacer
spacer
spacer
Arne Rehm
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River to Present Collaborative Methods at Neuroscience 2018

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 80 countries, will take place from November 3-7, in San Diego, California.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement